Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice
J. Clin. Invest. Chang-yun Hu, et al. 117:3857 doi:10.1172/JCI32405 [Go to this article.]

Figure 6
Histology and insulitis scores following 2H7 or IgG treatment. (A) Sections of pancreas illustrating islets taken from euglycemic hCD20/NOD mice at 2 months after treatment with 2H7 (top panels) or IgG antibody (lower panels) administered (Rx) at 4 weeks (left panels) or 9 weeks (right panels) of age. Magnification, ×100. (B) The graph illustrates different insulitis scores following treatment: I, treatment at 4 weeks, observation 1 month after treatment; II, treatment at 4 weeks, observation 2 months after treatment; III, treatment at 9 weeks, observation 1 month after treatment; and IV, treatment at 9 weeks, observation 2 months after treatment. Islets were examined from at least 3 euglycemic mice in each group and insulitis scored in 16–56 islets. When the insulitis scores were compared between 2H7 and IgG treatment within each of the 4 groups, we found P < 0.0001 for each group, which was statistically significant, correcting for multiple comparisons.